Pacira BioSciences Inc.

PCRX

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase2 readout (Enekinragene Inzadenovec (PCRX-201)): Nov 2026. Short interest: 29.1% of float.

Catalysts

Phase 2Q1 2006SKY0402Inguinal HerniaNCT01203644

Primary: Time to First Use of Supplemental Pain Medication (Through 96 hours postdose)Enrollment:76/76RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2006SKY0402Postoperative PainNCT01206595

Primary: Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain (Through 96 hours postdose)Enrollment:58/58RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2007SKY0402Postoperative PainNCT00529126

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) Pain Intensity Scores From 0 Through 72 Hours (0 to 72 hours)Enrollment:100/100Sites: 7RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2008SKY0402 + bupivacaine HClPostoperative PainNCT01206608

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) at Rest (NRS-R) and With Activity (NRS-A) Pain Intensity Scores (Through 96 hours postdose)Enrollment:40/40Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2009Bupivacaine HClPostoperative PainNCT00745290

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores (through 72 hours post surgery)Enrollment:245/245Sites: 19RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2NegativeQ1 2009Low Dose SKY0402Postoperative PainNCT00807209

Primary: Amount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours. (72 hours)Enrollment:3/3Sites: 5RANDOMIZED, TREATMENT

Phase 3PositiveQ1 2009Bupivacaine HClHemorrhoidsNCT00744848

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores (through 96 hours)Enrollment:204/204Sites: 20RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 3NegativeQ1 2009SKY0402PainNCT00813111

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores (through 72 hours)Enrollment:136/136Sites: 15RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2PositiveQ3 2009Bupivacaine HClPostoperative PainNCT00485693

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores Through Postoperative Day 4 (0 to 96 hours)Enrollment:138/138Sites: 9RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2009SKY0402HemorrhoidNCT00890721

Primary: The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo. (72 hours)Enrollment:189/189Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2009SKY0402Bunion, Hallux ValgusNCT00890682

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores (0-24 hours)Enrollment:193/193Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2011Facial WrinklesNCT01167140

Primary: Number of Participants With Effectiveness and Safety Success (Up to 4 months)Enrollment:42/42Sites: 1NA, TREATMENT

Phase 2Q1 2012FX005Osteoarthritis, KneeNCT01291914

Primary: Change from baseline in the WOMAC A score (pain subscale) (at 4 weeks post treatment)Enrollment:140/140Sites: 13RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2012Facial Wrinkles, Skin AgingNCT01447342

Primary: Effectiveness success (Up to 4 months)Enrollment:54/54Sites: 3NA, TREATMENT

Phase 2Q4 2012FX006 10 mgOsteoarthritis of the KneeNCT01487200

Primary: Change From Baseline in 24-hour Weighted Mean Serum Cortisol (Days 1-2, Days 14-15 (Week 2) and Days 42-43 (Week 6))Enrollment:24/24Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2013FX006Osteoarthritis of the KneeNCT01487161

Primary: Change From Baseline to Week 8 in Weekly Mean of the Average Daily (24-hour) Pain Intensity Score for FX006 60 mg vs TCA IR 40 mg (8 weeks)Enrollment:229/229Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2013EXPAREL 266 mgPosterolateral Thoracotomy, Postoperative PainNCT01802411

Primary: Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours (0-72 hours postsurgery)Enrollment:191/191Sites: 21RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2013Postoperative PainNCT01683071

Primary: Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours (0-72 hours)Enrollment:297/297Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2014FX006 10 mgOsteoarthritis of the KneeNCT02003365

Primary: Concentration of Triamcinolone Acetonide in Synovial Fluid (12 to 20 weeks)Enrollment:50/50Sites: 3NON_RANDOMIZED, TREATMENT

Phase 3Q4 2014Facial Wrinkles, Skin AgingNCT01379365

Primary: Wrinkle Severity and incidence of device-related serious adverse events (Up to 4 months)Enrollment:88/88Sites: 1NA, TREATMENT

Phase 2PositiveQ4 2015FX006 32 mgOsteoarthritis of the KneeNCT02116972

Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain Intensity Scores for 32 mg FX006 Versus Placebo (Baseline and Week 12)Enrollment:310/310Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016FX006Osteoarthritis of the KneeNCT02357459

Primary: Change From Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hr) Pain (ADP) Intensity Scores for 32 mg FX006 Versus Placebo (Baseline and 12 Weeks)Enrollment:486/486Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016Bupivacaine liposomeDental PainNCT02517905

Primary: Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours (0-48 hours)Enrollment:166/166Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2016FX006 32 mgPost-traumatic Osteoarthritis of the KneeNCT02468583

Primary: Average Change From Baseline in the Weekly Mean of the Average Daily (24-hour) Pain Intensity Scores Over Weeks 5 to 10 (5-10 Weeks)Enrollment:6/6Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2016FX006 32 mgOsteoarthritis of the KneeNCT02637323

Phase 2PositiveQ4 2016FX006 32 mgOsteoarthritis of the Knee, Type 2 Diabetes MellitusNCT02762370

Primary: Change From Baseline for Average Blood Glucose (mg/dL) (Baseline and 72 Hours post intra-articular (IA) injection)Enrollment:33/33Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2017bupivacaine liposome injectable suspensionPainNCT02713230

Primary: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores (0-48 hours)Enrollment:156/156Sites: 20RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ4 2017DepoTXATotal Knee ArthroplastyNCT02922582

Primary: Area Under the Plasma Concentration-versus-time Curve From Time 0 Extrapolated to Infinity After Drug Administration (Baseline; 5, 15, and 30 min; at 1, 2, 4, 6, 8, 12, 16, and 24 hours after study drug administration for all treatment groups. Additional blood samples were collected at 36, 48, 60, 72, and 96 hours for DepoTXA-treated subjects.)Enrollment:16/16Sites: 5RANDOMIZED, SINGLE, TREATMENT

Phase 2PositiveQ1 2018FX006 32 mgBilateral Knee OsteoarthritisNCT03378076

Primary: Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma (43 days)Enrollment:24/24Sites: 3RANDOMIZED, TREATMENT

Phase 3Q3 2018FX006 32 mgOsteoarthritis of the KneeNCT03046446

Primary: Total Number of Treatment Emergent Adverse Events (TEAEs) in Patients With Symptomatic Osteoarthritis (OA) of the Knee Who Received Two Doses of 32 mg FX006 (Up to 52 Weeks)Enrollment:208/208Sites: 17NA, TREATMENT

Phase 2Q4 2018FX006 32 mgOsteoarthritis of the Shoulder, Osteoarthritis of the HipNCT03382262

Primary: Concentration of Triamcinolone Acetonide (TA) in Blood Plasma (12 Weeks)Enrollment:55/55Sites: 6RANDOMIZED, TREATMENT

Phase 3NegativeQ3 2019FX006Osteoarthritis, HipNCT03793010

Primary: Change in WOMAC A (Pain) Score at Week 12 (Baseline and Week 12)Enrollment:70/70Sites: 32RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2019ExparelPostoperative Pain ManagementNCT03682302

Primary: Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity (15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery))Enrollment:98/98Sites: 17RANDOMIZED, TREATMENT

Phase 2Q4 2019FX006 32 mgOsteoarthritis, HipNCT04065074

Primary: Number of Patients With Successful Study Drug Administrations (Day 1)Enrollment:16/16Sites: 5NA, OTHER

Phase 3PositiveQ4 2019FX006 32 mgOsteoarthritis, KneeNCT03529942

Primary: Mean Standardized Change in Synovial Volume (SV) at 6 Weeks (Baseline to Week 6)Enrollment:129/129Sites: 10NA, TREATMENT

Phase 2NegativeQ2 2020FX006Osteoarthritis of the Shoulder, Adhesive CapsulitisNCT04160091

Primary: Area Under the Curve of the Change From Baseline in the Weekly Mean of the Daily Shoulder Pain With Movement (Baseline to 8 weeks)Enrollment:19/19Sites: 27RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2020EXPAREL 13.3Mg/mL Suspension for InjectionBunion, Metatarsophalangeal Fusion, Midfoot FusionNCT03954639

Primary: Magnitude of analgesic effect (0 hours to 96 hours)0RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2021ExparelLower Extremity Surgery, Bunion, Metatarsophalangeal FushionNCT04518462

Primary: Magnitude of the Analgesic Effect (NRS Pain Intensity) (AUC) (Post surgery - 96 hours)Enrollment:121/121Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2022bupivacaine liposome injectable suspensionKnee Osteoarthritis, Pain ManagementNCT05139030

Phase 3Q3 2022Bupivacaine liposome injectable suspension 266 mgBunionectomy, Hallux ValgusNCT05157841

Phase 2NegativeQ4 2025ZilrettaOsteoarthritis of HipNCT06977568

Phase 2Q4 2026Enekinragene Inzadenovec (PCRX-201)Osteoarthritis (OA) of the KneeNCT06884865

Primary: Incidence (number and percent) of treatment-emergent adverse events (TEAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52 (Week 1 through Week 52.)Enrollment:Target 135Sites: 40RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026ZILRETTAGlenohumeral OsteoarthritisNCT06269705

Primary: Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placebo (Week 12)Enrollment:Target 150Sites: 32RANDOMIZED, SINGLE, TREATMENT

Pacira BioSciences Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research